Regeneron Pharmaceuticals, Inc. (REGN) Misses Q1 EPS by 36c
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $784.85 -0.58%
EPS Growth %: +35.2%
Financial Fact:
Cost of goods sold: 29.9M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +35.2%
Financial Fact:
Cost of goods sold: 29.9M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 EPS of $0.58, $0.36 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $626 million versus the consensus estimate of $609.04 million.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
- UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
